USA, Canada and Western Europe (the traditional developed world). If there was a solid reason to include Australia that might work, but I don't know too much about clinical trials over there.
I think $1.50 should be a minimum price target in a buyout. Even that is only a $170 million enterprise value. Would be a reasonable valuation for both sides... But, I agree with you that we can't get there from here with just a buyout. Much too high of a premium.